

In re Hansen
US Patent Application No. 10/671,065

Page 10 of 12

REMARKS

Amendments to the claims

Claims 1-31 have been allowed with Notice of Allowance mailed April 15, 2005.

Claims 1 and 15 have been amended in respect of purely formal matters.

In sole independent claim 1 the word "of" has been inserted in the sentence now reading "and a drained volume position in which the first membrane surface in a stretched state abuts and substantially conforms to the general configuration of the first wall portion".

In dependent claim 15 the reference numeral (328) has been deleted.


In re Hansen
US Patent Application No. 10/671,065

Page 12 of 12

CONCLUSION

In view of the above, it is respectfully submitted that the proposed amendments to the claims do not affect the scope of any of the claims and that correspondingly no additional search or examination is required. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner should feel free to contact applicant's attorney by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,



Marc A. Began, Reg. No 48,829
Novo Nordisk® Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE

In re Hansen
US Patent Application No. 10/671,065

Page 10 of 12

REMARKS

Amendments to the claims

Claims 1-31 have been allowed with Notice of Allowance mailed April 15, 2005.

Claims 1 and 15 have been amended in respect of purely formal matters.

In sole independent claim 1 the word "of" has been inserted in the sentence now reading "and a drained volume position in which the first membrane surface in a stretched state abuts and substantially conforms to the general configuration of the first wall portion".

In dependent claim 15 the reference numeral (328) has been deleted.

In re Hansen
US Patent Application No. 10/671,065

Page 12 of 12

CONCLUSION

In view of the above, it is respectfully submitted that the proposed amendments to the claims do not affect the scope of any of the claims and that correspondingly no additional search or examination is required. The Commissioner is hereby authorized to charge any fees in connection with this application and to credit any overpayments to Deposit Account No. 14-1447. The Examiner should feel free to contact applicant's attorney by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: June 28, 2005



Marc A. Began, Reg. No 48,829
Novo Nordisk® Inc.
Customer Number 23650
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE